Inhibitory alpha-2 adrenoceptors in human adipose tissue.
D015057:1-Naphthylamine / Q000031:analogs & derivatives / Q000494:pharmacology; D000273:Adipose Tissue / Q000378:metabolism*; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D001665:Binding Sites / Q000187:drug effects; D003000:Clonidine / Q000494:pharmacology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D066298:In Vitro Techniques; D008066:Lipolysis / Q000187:drug effects*; D010646:Phentolamine / Q000494:pharmacology; D011941:Receptors, Adrenergic / Q000187:drug effects*; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects* / Q000502:physiology; D013806:Theophylline / Q000494:pharmacology; D015016:Yohimbine / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D007093:Imidazoles; D011941:Receptors, Adrenergic; D011942:Receptors, Adrenergic, alpha; D015016:Yohimbine; D015057:1-Naphthylamine; D013806:Theophylline; D003000:Clonidine; C005370:tramazoline; D010646:Phentolamine